With better understanding of molecular mechanisms of carcinogenesis, cell self-renewal and uncontrolled growth, metastasis, and other landmarks of cancer, progress has been made in developing and obtaining FDA approval of biological therapies targeting oncogenic signaling driver molecules including vascular-endothelial growth factor (VEGF) and its receptor VEGF-R [2], epidermal growth factor receptor (EGFR) [3], and human epidermal growth factor receptor-2 (HER2/Neu) [4]. This evidence concerns the gene EGFR and cancer.